3 Undervalued Small Caps With Insider Buying In Global Markets

In recent weeks, global markets have experienced mixed performances, with U.S. stock indexes nearing record highs and small-cap stocks trailing behind larger indices like the S&P 500. Amid this backdrop of rising inflation and cautious monetary policies, investors are increasingly looking at small-cap stocks for potential opportunities that might be overlooked in broader market trends. Identifying promising small-caps often involves examining factors such as insider buying, which can signal confidence in a company's future prospects despite current economic uncertainties.

Top 10 Undervalued Small Caps With Insider Buying

Name	PE	PS	Discount to Fair Value	Value Rating
Maharashtra Seamless	10.3x	1.6x	47.18%	★★★★★☆
Gamma Communications	23.1x	2.4x	32.85%	★★★★☆☆
Avia Avian	13.7x	3.1x	20.08%	★★★★☆☆
ABG Sundal Collier Holding	11.6x	1.8x	23.20%	★★★★☆☆
Logistri Fastighets	12.3x	8.7x	37.12%	★★★★☆☆
CVS Group	29.6x	1.2x	36.38%	★★★★☆☆
Optima Health	NA	1.5x	45.52%	★★★★☆☆
Mark Dynamics Indonesia	12.7x	4.1x	3.26%	★★★☆☆☆
Fourlis Holdings	8.2x	0.4x	-190.26%	★★★☆☆☆
Mukand	15.3x	0.3x	3.10%	★★★☆☆☆

Click here to see the full list of 183 stocks from our Undervalued Small Caps With Insider Buying screener.

Here we highlight a subset of our preferred stocks from the screener.

Sparebanken Sør (OB:SOR)

Simply Wall St Value Rating: ★★★☆☆☆

Overview: Sparebanken Sør is a financial institution primarily engaged in providing banking services across retail and corporate markets, with a market capitalization of NOK 7.79 billion.

Operations: The company's revenue is primarily driven by the Retail Market (NOK 1.68 billion) and Corporate Market (NOK 1.32 billion) segments. Operating expenses, including general and administrative expenses, impact net income margins, which have shown variability over time, reaching up to 20.29%.

PE: 10.9x

Sparebanken Sør, a smaller player in the financial sector, exhibits potential for growth despite its reliance on external borrowing for 53% of its funding. Earnings are projected to grow by 26% annually, and insider confidence is evident with Tor Steinsland purchasing 2,000 shares valued at NOK 405,679. The bank's recent earnings report showed an increase in net interest income to NOK 3.35 billion from NOK 3.05 billion last year.

• Unlock comprehensive insights into our analysis of Sparebanken Sør stock in this valuation report.

• Learn about Sparebanken Sør's historical performance.

Apex Mining (PSE:APX)

Simply Wall St Value Rating: ★★★★★☆

Overview: Apex Mining is a Philippines-based company engaged in the exploration and extraction of gold, silver, copper, lead, and other precious metals with a market capitalization of approximately ₱11.68 billion.

Operations: APX generates revenue primarily from its operations, with a notable increase in gross profit margin from -16.54% in 2014 to 46.86% by September 2024, indicating significant improvements in cost management and operational efficiency over the years. Operating expenses have varied but remained a crucial factor affecting profitability, while non-operating expenses have also impacted net income margins. The company's net income margin showed an upward trend, reaching approximately 30.62% by September 2024, reflecting enhanced profitability and financial health over time.

PE: 6.1x

Apex Mining's financial landscape is intriguing, with earnings projected to grow 9.2% annually. Despite relying solely on external borrowing for funding, which carries inherent risks, insider confidence is evident through recent share purchases in the past year. The company's strategic moves include appointing Billy G. Torres as Chief Finance Officer in October 2024, signaling a potential shift in financial strategy. Apex's small cap status offers unique growth opportunities within its sector amidst these developments.

• Click here and access our complete valuation analysis report to understand the dynamics of Apex Mining.

• Evaluate Apex Mining's historical performance by accessing our past performance report.

Shanghai Haohai Biological Technology (SEHK:6826)

Simply Wall St Value Rating: ★★★★☆☆

Overview: Shanghai Haohai Biological Technology is a company focused on the research, development, manufacture, and sale of biological materials and medical products with a market capitalization of CN¥16.32 billion.

Operations: Haohai's revenue streams have shown growth, with a recent figure of CN¥2.70 billion for the period ending December 2024. The company's cost structure is primarily driven by COGS and operating expenses, with sales and marketing being a significant component. Notably, the gross profit margin has experienced fluctuations over time, reaching 69.10% in September 2024 before peaking at 100% in December 2024 due to an anomaly in reported costs. Net income margins have varied as well, with a recent figure of approximately 15.57%.

PE: 13.4x

Shanghai Haohai Biological Technology, a player in the biotech sector, recently reported annual sales of CNY 2.7 billion and net income of CNY 420 million for 2024, showing modest growth from the previous year. The company completed a share buyback worth CNY 30.58 million by December 2024. Insider confidence is evident as CFO Minjie Tang purchased 10,000 shares for approximately CNY 265,000 in late 2024, increasing their holdings significantly. While reliant on external borrowing, earnings are projected to grow annually by over 20%.

• Navigate through the intricacies of Shanghai Haohai Biological Technology with our comprehensive valuation report here.

• Gain insights into Shanghai Haohai Biological Technology's past trends and performance with our Past report.

Where To Now?

• Unlock our comprehensive list of 183 Undervalued Small Caps With Insider Buying by clicking here.
• Have a stake in these businesses? Integrate your holdings into Simply Wall St's portfolio for notifications and detailed stock reports.
• Unlock the power of informed investing with Simply Wall St, your free guide to navigating stock markets worldwide.

Seeking Other Investments?

• Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
• Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.
• Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com